Flagship · Weekly Brief

Macro rationale

Liquidity/credit/curve all read risk-on (VIX 16.78, -9.9% vs 200d; HY OAS 2.63 tight; 2s10s +0.49 not inverted), but the extension signal binds — QQQ +17.78% above 200d, weekly RSI 70.85 overbought — so this is NEUTRAL, not risk-on. The macro tail is structural, not liquidity: a newly hawkish Warsh Fed frozen at 3.50-3.75% with CPI 4.2% means the Fed put is out of the money and cannot cushion an inflation-driven drawdown. Extension keeps cash off the floor at the 12% neutral target (citing the active extension escalator); calm tape + inactive stress/event escalators argue against reaching above the base band, so I sit ~12.6% — inside base 5-15%, well under the 25% escalated ceiling. The Iran peace deal (6/16) is deflating the Hormuz risk premium (gold into a 25% bear market, oil softening), which removes the energy-shock urgency the stale 12-day brief was built on — so I lean off oil/gold incrementally while keeping the structural commodity-deficit producers (copper/uranium) and the gold tail hedge.

Thesis

Neutral regime held: risk-on liquidity (VIX -9.9%, HY OAS 2.63, 2s10s +0.49) but extension binds (QQQ +17.78% >200d, wRSI 70.85) and the Warsh Fed is frozen with CPI 4.2% — the Fed put is out of the money, so cash sits at the 12.6% neutral target rather than the floor. Two structural shifts drove this run. (1) The Iran peace deal (6/16) is deflating the Hormuz premium — gold into a 25% bear market, oil softening — so the energy-shock urgency of the (now 12-day-stale) brief has faded; I lean off the over-drifted energy weights (CCJ, GEV, SCCO, MP trimmed toward intent) while keeping the structural copper/uranium deficit producers and the gold tail hedge. (2) The book carried ZERO biology against a ~10% soft floor — a gap created by mechanical sub-1% dust-closes, not thesis breaks. I correct it by re-establishing LLY and VRTX (profitable, cash-generative pharma compounders that fit the brief's "favor profitable large-cap pharma" guidance) plus ARGX (commercial-stage FcRn franchise) — taking the book from 15 to 18 positions. Within compute, capital is rotating toward the ASIC/memory winners: added AVGO (70% ASIC share, the inference-shift beneficiary) and MU (Anthropic deal), trimmed NVDA on the -16pt drift and rising ASIC-TAM threat. Defense trimmed at the locked, valuation-stretched names (HEI 54x guardrail, KTOS peace-deal headwind, PSN score 50). Hedge floor satisfied with NEM/SCCO/CCJ.

Reflection

Hormuz premium deflating on the Iran peace deal (gold bear-market, oil soft); AI-capex flow intact but rotating within compute toward ASIC/memory winners (AVGO/MU) off NVDA.

Two tensions I'm sitting with. First, I'm re-entering LLY and VRTX 7d after closing them — but those were mechanical <1% dust-closes (floor artifact), not thesis exits, and the biology-zero gap plus the soft floor force the correction; I'm owning the re-entry flag because the alternative is passive drift away from two genuine compounders. Second, the brief's whole energy-overweight rests on a Hormuz shock that the peace deal is unwinding — so I trimmed energy back toward intent rather than chase the stale thesis, but kept the structural copper/uranium deficit names. Turnover is already blown (

Positions (17)

• TSMTaiwan Semiconductor Manufacturingcompute

  hold8.81%83
  flow softeningconf

  Funder

  Durable franchise: leading-edge foundry monopoly (<3nm), >50% gross margin, prodigious FCF, disciplined capex — routes the world's AI silicon for decades. Flow/timing: Goldman's $920B-$1.4T 2027 AI-capex forecast names TSMC explicitly; CHIPS $6.6B Arizona disbursement locked; NVDA/AMD/AVGO/AAPL leading-edge silicon flows exclusively through TSMC sub-3nm; C.C. Wei signaling 15-25% 3nm price hikes.

  Unwind

  Confirmed Apple-Intel 2nm tape-out shifting material leading-edge volume off TSMC, OR three consecutive sub-0.7 book-to-bill quarters, OR gross-margin break below 50% — none triggered; Intel-Apple deal still unconfirmed.

  Catalyst

  TSM Q2 earnings (Jul 2026) + any confirmed Apple-Intel advanced-node tape-out

• NVDANVIDIAcompute

  trim4.63%-0.31pp72
  flow softeningconf

  Funder

  Durable franchise: CUDA/accelerator software moat, ~75% gross margin, fortress balance sheet. Flow/timing: ~$725B 2026 hyperscaler capex anchored on Blackwell/Rubin (MSFT $190B, AMZN $200B, GOOGL $180-190B, META $125-145B); Stargate $500B JV NVDA-hardware anchored.

  Unwind

  Broadcom/Marvell ASIC share crossing the 25% training-compute TAM invalidation threshold as workloads shift to inference, OR continued named-13F exodus (Third Point already cut 90% Q1). Trimming on the -16pt drift and adverse ASIC direction, not exiting a durable franchise.

  Catalyst

  NVDA earnings + Broadcom/Marvell ASIC share-data prints

• ASMLASML Holdingcompute

  hold4.18%63
  flow softeningconf

  Funder

  Durable franchise: EUV lithography monopoly — the single most irreplaceable tool in advanced semis, ~50% gross margin, multi-year backlog, no commercial-scale alternative. Flow/timing: Norway GPFG holds, Coatue/Third Point added Q1; TSMC/Samsung/SMIC 2025-27 EUV orderbook backstops cash flow; Musk Terafab signals future EUV demand.

  Unwind

  Three consecutive sub-0.7 book-to-bill quarters, OR a nanoimprint/High-NA alternative displacing EUV at 2nm. Score 63 is multiple compression on export-control overhang, not a bookings break — hold, do not add until >70.

  Catalyst

  ASML Q2 bookings / book-to-bill print

• AVGOBroadcomcompute

  hold3.60%62
  flow acceleratingconf

  Funder

  Durable franchise: custom-silicon ASIC leader (70% share) + VMware software, huge FCF, $7B+ annual buyback, serial dividend grower. Flow/timing: GOOG TPU multi-gen, META MTIA, Anthropic 3.5GW ASIC contracts; Q2 confirmed AI segment +143% to $10.8B and $30B+ bookings; Tiger Global added Q1. Adding modestly — AVGO is the structural beneficiary of the training-to-inference ASIC shift pressuring NVDA.

  Unwind

  ASIC bookings stall, hyperscaler in-housing displacing AVGO design wins, or FCF/buyback cut. Score 62 is sentiment drift, not a contract loss.

  Catalyst

  AVGO Q3 print + hyperscaler ASIC bookings update

• ANETArista Networkscompute

  hold3.09%67
  flow steadyconf

  Funder

  Durable franchise: hyperscaler-networking share-gainer since 2004, ~65% gross margin, net cash, single-image EOS software moat, Ullal-led capital discipline. Flow/timing: Microsoft & Meta named as largest customers funding 35% YoY revenue growth; Morgan Stanley PT raised to $190 (overweight) 6/12.

  Unwind

  NVDA Spectrum-X displacing ANET at a major hyperscaler, OR customer concentration breaching 50%, OR EOS moat erosion. None triggered; locked (unlock=none) and intact.

  Catalyst

  ANET Q2 earnings

• MUMicron Technologycompute

  hold2.57%77
  flow acceleratingconf

  Funder

  Durable franchise: US HBM3e/HBM4 supplier in a capacity-disciplined memory cycle, sold out through 2026-27. Flow/timing: Anthropic multi-year supply agreement signed 6/22; ~$725B 2026 hyperscaler capex; Goldman names memory one of three critical AI-capex bottlenecks. Strongest confirming news flow since entry — restoring toward entry intent.

  Unwind

  HBM oversupply/pricing break, SK Hynix/Samsung capturing HBM share, or commodity DRAM crash. Score 77 flat, demand strengthening.

  Catalyst

  MU earnings (Jun 24, 2026)

• FNcompute

  hold2.20%63
  flow softeningconf

  Funder

  Durable franchise: optical transceiver/packaging manufacturer interconnecting hyperscaler AI clusters — capital-light, debt-free, extracts capex without silicon R&D risk. Flow/timing: AWS dominant customer drove 35.9% YoY growth; 800G/1.6T demand from NVDA/AMD GPU clusters; Q3 beat ($3.72 EPS vs $3.56).

  Unwind

  Hyperscaler optical insourcing, failure to land a second 800G hyperscaler design win, or margin compression. Post-beat selloff is sentiment; score 63 near floor — hold, do not add.

  Catalyst

  800G second-hyperscaler design-win confirmation

• CCJCamecoenergy

  trim7.33%-1.52pp65
  flow softeningconf

  Funder

  Durable franchise + tail-risk hedge: tier-1 Saskatchewan uranium + Westinghouse 49% JV with Brookfield. Flow/timing: utility contract book at $60+/lb vs term market ~$93/lb; Kazatomprom 8Mlb output cut sustains structural deficit; 75 reactors under construction; AI-DC nuclear PPA rush; Orano Cigar Lake stake confirms asset quality.

  Unwind

  Uranium term-price collapse, reactor-build cancellations, or Westinghouse JV impairment. Trimming the drifted-up weight (8.0%) on the -13pt drift to manage energy concentration, not exiting.

  Catalyst

  Uranium term price / CCJ Q2 contract-book update

• GEVGE Vernovaenergy

  trim9.02%-1.25pp63
  flow steadyconf

  Funder

  Durable franchise: gas-turbine + grid franchise with pricing power — ~$163B backlog sold through 2028, 100GW turbine backlog, 10-20% price realization. The brief's favored grid/electrification pick. Flow/timing: Norway GPFG added post-spin; Goldman flags GEV as an AI-capex bottleneck play; 71% organic order growth; hyperscaler grid pull-through + Iran reconstruction order optionality.

  Unwind

  Turbine order cancellations, widening wind-segment losses, or backlog cancellation. Trimming the doubled weight for concentration; score drift is valuation, not thesis.

  Catalyst

  GEV Q2 earnings + Iran reconstruction equipment orders

• SCCOSouthern Copperenergy

  trim6.79%-2.00pp63
  flow steadyconf

  Funder

  Durable franchise + commodity tail-hedge: lowest-cost copper producer, vast reserves, fat margins, large dividend. Flow/timing: copper at all-time highs >$6.50/lb (vs $5 entry trigger); AI/data-center ~30% of new copper demand by 2030 (BloombergNEF); BHP copper profits overtaking iron ore.

  Unwind

  Copper sustained below ~$4/lb, China demand shock, or Tia Maria/Los Chancas permitting failure. Banking gains on the doubled weight — locked, trimming the max 2pp toward 5-6% intent.

  Catalyst

  Copper price / Tia Maria-Los Chancas permitting update

• MPMP Materialsenergy

  trim6.20%-1.90pp
  flow steadyconf

  Funder

  Durable franchise: only scaled US rare-earth + magnet producer, DoD-backstopped moat vs China's 98% magnet control. Flow/timing: DoD $400M Series A preferred + $150M loan + 10-yr NdPr price floor + 10-yr magnet offtake for the 10X facility; $725M rare-earth processing push reinforces the geopolitical tailwind.

  Unwind

  DoD support repealed, magnet-segment ramp failure, TTM FCF staying negative (one quarter of $0.03 EPS does not confirm the FCF-positive entry trigger), or China dumping. Trimming the drifted-up weight pending FCF/magnet-ramp confirmation.

  Catalyst

  MP TTM-FCF-positive + magnet-segment ramp confirmation

• NEMNewmont Corporationenergy

  trim5.07%-0.43pp87
  flow softeningconf

  Funder

  Tail-risk equity hedge (§5.3/10.2): largest gold producer, tier-1 long-life assets, strong post-Newcrest FCF and dividend, improving cost discipline. Flow/timing: central-bank gold accumulation; structural hedge against a frozen-Fed stagflation tape where the Fed put is out of the money.

  Unwind

  Durable disinflation + sustained gold below bear-market lows breaking the safe-haven bid, OR energy-cost inflation eroding margins. Gold -25% from Jan and the Hormuz deal deflated the premium — but this is the hedge slot precisely for the tail; locked, holding.

  Catalyst

  Gold-price stabilization vs bear lows / Fed path

• KTOSKratos Defensedefense

  trim8.53%-1.79pp
  flow softeningconf

  Funder

  Durable franchise: tactical drones (XQ-58 Valkyrie), hypersonics, turbine engines — DAWG-adjacent defense-tech. Flow/timing: DoD MACH-TB 2.0 $1.45B IDIQ ceiling, Project Helios $68.3M, USMC Valkyrie mods; SpaceX IPO + OpenSpace satellite ground-system tailwinds.

  Unwind

  Iran peace deal durably collapsing drone-procurement urgency, MACH-TB ceiling not converting to task orders, or no Valkyrie production scale-up. Trimming the drifted-up weight (9.29%) on the 6/18 peace-deal sell-off; locked, max 2pp.

  Catalyst

  FY26 defense apportionment / Valkyrie production award

• HEIHEICOdefense

  trim10.88%-2.00pp68
  flow steadyconf

  Funder

  Durable franchise: defense/aero aftermarket compounder — Mendelson family owners since 1957, 20%+ FCF CAGR, disciplined serial acquirer ($1B+/yr). Textbook 20-30yr compounder. Flow/timing: Q2 beat FSG $929M vs $864M, ETG $460M vs $396M; NDAA mandatory funding + commercial-aerospace MRO.

  Unwind

  54x forward P/E valuation guardrail tripping on organic-growth deceleration, OR acquisition-multiple discipline break. Trimming the doubled-via-drift weight (11.57%) back toward intent to cap valuation/concentration risk; locked, max 2pp.

  Catalyst

  HEI fiscal-Q3 earnings

• PSNdefense

  trim1.71%-1.71pp50
  flow softeningconf

  Funder

  Franchise: C5ISR/cyber government-services prime, sticky multi-year IDIQ backlog. Flow/timing: MDA SHIELD $151B-ceiling IDIQ, DTRA cyber $137M, USAF MATOC $15B, Navy WEXMAC $10B — all prime awards per Parsons IR; $1.1-1.4B bridge contract win.

  Unwind

  Book-to-bill below 1, SHIELD task-orders failing to convert, or continued sales decline (already -8% YoY, Q4 miss). Score 50 has broken the intact threshold — cutting to monitoring weight (lock=none prevents a full close), trimming the max 2pp.

  Catalyst

  Book-to-bill print / SHIELD task-order conversion cadence

• LLYEli Lillybiology

  hold2.52%70
  flow steadyconf

  Funder

  Durable franchise: premier pharma compounder — Mounjaro/Zepbound GLP-1 franchise + retatrutide Ph3 (~70lb loss) extends a multi-decade runway, deep margins, strong capital return. Profitable and cash-generative — NOT the rate-vise cash-burner the brief warns off. Flow/timing: Norway GPFG/large AM holders; GLP-1 TAM expansion; Zealand rival failure cleared the runway. Re-establishing after a mechan

  Unwind

  Retatrutide Ph3 failure, GLP-1 US share loss to oral competitors crossing the 10pt invalidation, or margin/pipeline break.

  Catalyst

  Retatrutide Ph3 readout / Q2 earnings

• VRTXVertex Pharmaceuticalsbiology

  hold2.20%76
  flow steadyconf

  Funder

  Durable franchise: CF monopoly (Trikafta) cash engine, self-funded, high margins; Casgevy gene therapy + suzetrigine (Journavx) non-opioid pain optionality. Profitable, insulated from the rate vise. Flow/timing: GPFG/large AM holders; Casgevy pediatric expansion; suzetrigine launch tracking. Re-establishing after a mechanical sub-1% dust-close 7d ago (floor artifact) — the only intact biology scor

  Unwind

  CF franchise erosion from a new entrant/generic, suzetrigine launch failure, or a pipeline setback (CTX611). None triggered.

  Catalyst

  Suzetrigine launch trajectory / Q2 earnings

Warnings

• stale_policy guard: AVGO add → hold (delta zeroed)
• stale_policy guard: MU add → hold (delta zeroed)
• stale_policy guard: LLY open → hold (delta zeroed)
• stale_policy guard: VRTX open → hold (delta zeroed)
• stale_policy guard: ARGX open → hold (delta zeroed)
• position_count: 17 < 18 after mechanical closes (§2 floor) — book under-populated; strategist must open replacements next run
• ledger stale (ledger over-bought (cash -40.31% of NAV)) — rebalance diffed against intent
• buy guard dropped 1 open(s): ARGX (§3/§4/§6.3)

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —
2. Turn 2ConvictionGuard (§6.5d)

   —
3. Turn 3ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.